|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Myocardial mRNA levels of interleukin-6, tumor necrosis factor-α, plasminogen activator inhibitor-1, angiotensin type 1 receptor, angiotensinogen, NADPH oxidase subunits (p47(phox), gp91(phox)), glutathione peroxidase-3. and connective tissue growth factor were increased in CRP/DM compared with Wt/DM.
|
21519150 |
2011 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that a PAI-1 specific inhibitor alleviated diabetes-induced delays in skin and muscle repair.
|
29311999 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Increased flux through HBP is required and sufficient for some of the metabolic effects of sustained, increased glucose flux, which promotes the complications of diabetes, e.g., diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase in cardiomyocytes and induction of TGF-beta and plasminogen activator inhibitor-1 in vascular smooth muscle cells, mesangial cells, and aortic endothelial cells.
|
16339923 |
2006 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin.
|
11887975 |
2001 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1), produced partly from liver is a risk factor for macrovascular and microvascular complications of diabetes.
|
18700166 |
2008 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Patients most likely to benefit from PAI-1 inhibition would be those at high risk for vascular events where PAI-1 is elevated, such as is observed in obesity, diabetes and the metabolic syndrome.
|
17896948 |
2007 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Elevated plasminogen activator inhibitor-1 may contribute to vascular disease in diabetes mellitus.
|
8960834 |
1996 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
From our longitudinal cohort study, we selectively recruited chronically stable HIV-infected individuals without diagnosis of diabetes mellitus at baseline (N = 62) to analyze the correlation of baseline inflammatory cytokines, including PAI-1 and whole-body insulin sensitivity, with 2-year follow-up, as measured by Matsuda Index.
|
28322572 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice.
|
25552599 |
2015 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
MTHFRA1298C and PAI-1 deletions were most frequent genetic variants in risk groups for MI in patients with diabetes mellitus (value of odds ratio sequentially [OR] = 3.79, p = 0.06 and [OR] = 5 × 10(8), p = 0.000).
|
22752805 |
2012 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Our meta-analyses suggest that the PAI-1 -675 4G/5G polymorphism might not be a risk factor for DM, DN, DR or diabetic CAD risk in the populations investigated.
|
24223897 |
2013 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Interaction between genotype and diabetes status was estimated for nine CVD risk factors [body fat mass (FAT), body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), log-transformed fibrinogen, log-transformed triglycerides, log-transformed urinary albumin : creatinine ratio (LACR), plasminogen activator inhibitor 1 (PAI-1), systolic blood pressure (SBP), and waist-to-hip ratio (WHR)], using a maximum likelihood variance decomposition technique.
|
12673782 |
2003 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Low-moderate arsenic exposure was positively associated with baseline fibrinogen in participants with diabetes and unexpectedly inversely associated with PAI-1.
|
28771557 |
2017 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The PAI-1 and ACE (D/I) gene polymorphisms were examined in a cohort of Chinese type 2 diabetic patients who had diabetes for an average of 14 years.
|
10652041 |
2000 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
|
21070757 |
2011 |